HopeStage
Back to all studies
CompletedNCT02589262

AUT00206 Safety, Blood Levels and Effects in Schizophrenia

About this titleRead the official source — NCT02589262
Medication studyAges 18–45United Kingdom
The study in practice

Understand this study

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Listed locations
LondonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2015
Recruitment status
Completed
Enrollment listed in the registry
Not clearly listed
Sponsor
Autifony Therapeutics Limited
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 45 Years
Official registry ID
NCT02589262
Official title
Show the full official title

A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Autifony Therapeutics Limited.

Did this study involve medication?

Yes. The study involved medication, including AUT00206.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies